The stock will trade on pipeline catalysts, not quarterly financials. Key events to watch: ASCO presentation of OP-3136 data (late May 2026) and top-line OPERA-01 Phase 3 data (fall 2026). The $505M cash position funds operations through these milestones. No revenue or earnings guidance was provided.
OLMA drugs
OLMA drug pipeline →Price Chart
Executive Summary
Olema Pharmaceuticals reported Q1 2026 financial results, with a net loss of $53.1M (vs $30.4M in Q1 2025) driven by increased R&D spending on late-stage trials. The company ended the quarter with $505.3M in cash and highlighted upcoming catalysts: top-line Phase 3 OPERA-01 data expected this fall and initial Phase 1 data for OP-3136 at ASCO. As a pre-revenue clinical-stage biotech, the widening loss was expected and the cash runway supports operations through key data readouts.
Key Financial Metrics
Key Facts
- Net loss for Q1 2026 was $53.1M, compared to $30.4M in Q1 2025
- Cash, cash equivalents, and marketable securities were $505.3M as of March 31, 2026
- GAAP R&D expenses were $49.2M in Q1 2026 vs $30.6M in Q1 2025
- GAAP G&A expenses were $8.8M in Q1 2026 vs $4.2M in Q1 2025
- Top-line data from Phase 3 OPERA-01 trial of palazestrant expected in fall 2026
- Initial Phase 1 clinical data for OP-3136 to be presented at ASCO in May 2026
- No revenue reported; company is a clinical-stage biopharmaceutical firm
Financial Impact
Net loss increased by $22.7M YoY to $53.1M; cash burn rate increased as R&D spending rose 61% to $49.2M
Risk Factors
- Phase 3 OPERA-01 trial failure would be a significant negative catalyst
- Cash burn rate is accelerating as R&D spending increases
- No approved products or revenue; fully dependent on clinical trial success
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-218142 |
| Document: olma-ex99_1.htm | 0001193125-26-218142 |
| Document: 0001193125-26-218142-index-headers.html | 0001193125-26-218142 |
| Document: 0001193125-26-218142-index.html | 0001193125-26-218142 |
| Document: 0001193125-26-218142.txt | 0001193125-26-218142 |
| 8-K Data (Synthetic) | 0001193125-26-218142 |
Track record
20 reports on OLMA
1 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +38.44% at T+60 after the Aug 9, 2026 report. 1 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.29 Now $7.36 +0.96% settles Feb 12
- Nov 12, 20264d ago 8-K Neutral 2/10 Entry $7.56 Now $7.36 −2.65% settles Feb 11
- Nov 10, 20266d ago Press Release Neutral 4/10 Entry $7.27 Now $7.36 +1.24% settles Feb 8
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $7.33 Now $7.36 +0.41% settles Feb 4
- Oct 16, 20264w ago SC 13D/A Neutral 2/10 Entry $7.11 Now $7.36 +3.52% settles Jan 14
- Oct 15, 20264w ago 8-K Neutral 2/10 Entry $6.58 Now $7.36 +11.85% settles Jan 13
- Oct 2, 20266w ago Press Release Neutral 2/10 Entry $8.25 Now $7.36 −10.79% settles Dec 30
- Aug 10, 202614w ago 8-K Neutral 5/10 No price data
- Aug 10, 202614w ago Press Release Neutral 4/10 Entry $10.43 to $7.54 Now $7.36 −29.43% ▼ −27.71% −27.22% vs SPY
- Aug 9, 202614w ago Institutional Cluster Bearish 6/10 Entry $11.94 to $7.35 Now $7.36 +38.36% ▲ +38.44% +36.03% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers